JUL 10, 2018 11:15 PM PDT

TdT Positive Cells - Not Just for Neoplasms

Terminal deoxyncleotidyl transferase (TdT) is a unique DNA polymerase molecule that is expressed by immature lymphoid cells, both normal and mutagenic.  As a cell ages, it loses the TdT expression capability.  Young lymph progenitor cells would be expected then to have this cell marker; cancerous lymph cells can be mutated versions of those young lymph progenitor cells growing out of control so increased TdT levels could be expected, and in fact have been used diagnostically in laboratory medicine.  TdT has been an identifiable marker since the late 1980s where it was found to be enhanced in acute undifferentiated leukemias, immature acute lymphoblastic leukemias, and in a fraction of cases of leukemic patients in blast crisis.  TdT acts by catalyzing the reaction that leads to the addition of deoxynucleotides to hydroxyl ends of oligonucleotides as part of DNA synthesis.  It also contributes to differences in antibody recognition sites by rearrangement of immunoglobulins or T-cell receptors.  It has long been associated with very undifferentiated neoplasms.

A new article published in the journal Human Pathology is a reminder that healthy lymph nodes and lymph cells can also express TdT because they are early lymphoid precursors; this is especially true in pediatric lymph nodes.  There are benign TdT positive lymph nodes in pediatric patients and this group focused on characterizing the presence of benign TdT positive cells and characterize the typical phenotype associated with their presence. 

Findings included that TdT was sparsely positive in all pediatric cases and in more than three quarters of adult lymph nodes evaluated (n=141).  It was noted that there was increased density of TdT positive cells in pediatric lymph nodes and TdT presence was not found to be associated with any clinical or histological factor other than identifying that these were lymphoid precursors with CD34 and CD10 also being expressed.

The study serves as a reminder to be mindful of the common phenotype of TdT positivity in early healthy lymphoid precursors and to carefully avoid misidentification of these cells as early neoplasm markers.

Sources: Human Pathology, International Journal of Biological Markers, American Journal of Clinical Pathology, Pathology Outlines,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
NOV 13, 2019
Genetics & Genomics
NOV 13, 2019
New Drug Targets for Lung Cancer Identified
Researchers at the Salk Institute have now learned why certain genetic mutations lead to cancer growth....
NOV 13, 2019
Cancer
NOV 13, 2019
Understanding aging: new research
We all do it every day, but there’s still so much we don’t understand about it. I’m talking about aging. But now new research published r...
NOV 13, 2019
Cancer
NOV 13, 2019
Infant with leukemia saved by liver cancer drug
A young child just months old recently successfully received cancer treatment for an uncommon type of leukemia. The drug used in the treatment was not a ta...
NOV 13, 2019
Cancer
NOV 13, 2019
Handheld device detects skin cancer
I can’t be the only one who has ever looked at a suspicious freckle and wondered, “Could this be skin cancer?” Of course, when 9,500 Amer...
NOV 13, 2019
Drug Discovery & Development
NOV 13, 2019
Researchers Can Now Reverse Skin Cancer
Ten years ago, just 5% of people with advanced melanoma (skin cancer) lived more than five years after being diagnosed. Now however, researchers from the I...
NOV 13, 2019
Cancer
NOV 13, 2019
Using temperature to awaken immune response to fight brain cancer
Glioblastoma is the most common form of adult brain cancer and also one of the most aggressive human cancers. Immunotherapy has yet to be shown proven effe...
Loading Comments...